What one GLP-1 price hides: the four-line cost, explained

A bundled baseline weight-management lab panel often lands around $239 out of pocket, before you have paid for a single dose of medication (PersonalLabs 2026; LabCorp OnDemand 2026). The cash-pay lines behind it run about $40 to $80 for a comprehensive metabolic panel, $38 to $75 for an A1C, and $45 to $85 for a lipid panel. None of that shows up in the one price most people are quoted when they start a telehealth GLP-1 program. You were quoted one price. Then the second, third, and fourth lines arrived, and the worried math started all over again. That gap, between the price you are told and the price you actually pay, is what this analysis is about, and it is exactly the question reporters are already chasing as the FDA's 2026 compounding proposal heads toward its comment close on June 29, 2026.

Short answer: sipra's finding is simple and, we think, defensible as ours: the all-in cost of a telehealth GLP-1 program is not one price. It is four separate lines. Patients are quoted the first and surprised by the other three. This is a guide to what to know before you sign up, and the short version is this: the bill has four lines, and most quotes show one. Individual results vary, and so do individual costs, but the structure of the bill is the same for almost everyone.

This is also a genuinely contested point. Telehealth marketers argue, not unreasonably, that a single headline price is the only number a shopper actually wants. Consumer-cost advocates and many clinicians disagree and say the practice sets up a surprise charge. We think the reality check is the four-line receipt itself: show all of it, and the debate mostly evaporates.

Here is the framework we built this piece around. Think of your monthly GLP-1 cost as four lines on a receipt, not a single sticker price:

• Medication. The line you are quoted up front. Public market estimates put brand-name GLP-1 medications at roughly $149 to $699 per month depending on the drug and the dose, with some cost-comparison tools citing $900 to $1,600 (GoodRx, Noom, Health Facts Journal, Telehealth Ally, Ivim Health, May 2026). These are third-party market estimates, not sipra figures. For independent reporting, see KFF Health News coverage of GLP-1 pricing.

• Titration. The dose steps up over time, and the price often steps up with it. The number you were quoted at the start may not be the number you pay in month three.
• Labs. Baseline bloodwork is a real, separate line. The bundled baseline panel commonly runs around $239 out of pocket, and follow-up labs add more later (PersonalLabs 2026; LabCorp OnDemand 2026). For context, the CDC's diabetes and A1C resources and the NIH/NIDDK overweight and obesity resources explain the baseline bloodwork most programs order.
• Physician follow-up. Some programs bundle visits; others bill per visit. Either way, it is a line, and it is rarely in the headline price.

Add the four lines and the real monthly cost can look very different from the one number on the landing page. We are not telling you which program is cheapest, and we make no savings claim. We are saying the bill has four lines, and most quotes show one. The Federal Trade Commission's guidance on negative-option and full-cost disclosure is the consumer-cost backdrop here: a price a shopper cannot see before they commit is the kind of charge regulators have flagged for years.

The medication line is easy to advertise. It is one number, it sounds like the whole story, and it is the number a shopper is looking for. The other three lines are harder to show because they move. Titration changes with the dose. Labs depend on what a clinician orders and where you get them drawn. Follow-up depends on whether visits are bundled or billed.

That is a reasonable business explanation. It is also exactly how a person ends up quoted one price and surprised by three. The fix is not outrage. It is disclosure: show all four lines before checkout, in plain language, so the person deciding can see the real shape of the cost.

Cost transparency in GLP-1 care is not a timeless explainer this month. It is pegged to a dated event. The FDA's 2026 compounding proposal, with its bulks list and the long-running 503A vs 503B debate over who can compound what, has its comment close on June 29, 2026. The compounding rule is, at its core, a fight about which GLP-1 products exist at which prices, and that is the medication line of the four-line bill.

Reporters covering the compounding proposal are already asking the cost question. When the medication market shifts, the other three lines (titration, labs, follow-up) do not disappear. They become more important, because a shopper comparing options needs the all-in number, not a medication price that may itself be in regulatory motion. That is why a price-transparency analysis lands now: the news peg is about price, and the missing three lines are the part the news peg tends to leave out.

The cited lab figures above are real and public, and they anchor the piece in a concrete, sourced number today. But the flagship number, the one we want reporters to cite by name, is not a public figure. It is something we measure ourselves: how many of the top telehealth GLP-1 providers hide the all-in monthly cost until checkout.

That number is to be measured via the sipra Billing-Transparency Index mystery-shop of N providers. We have not run it yet, so we are not going to put a number on it. Inventing one would defeat the entire point of a transparency index.

When the index runs, each provider earns a transparency grade based on a short, repeatable checklist:

• Is the medication price visible before you create an account?
• Is titration pricing disclosed (does the quote change as the dose steps up)?
• Are lab costs shown, or only mentioned?
• Is physician follow-up priced (bundled or per visit), in writing?
• Can a shopper see the all-in monthly cost before reaching checkout?

The headline finding will be the share of the top N providers that hide the all-in cost until checkout. The supporting findings will be the per-line transparency grades.

This is an original-data piece, so the method is on the table.

• Sample: the top N telehealth GLP-1 providers by public visibility (N and the provider list to be locked before the run).
• Source: each provider's own publicly disclosed pricing pages and checkout flow, captured on the run date. No private or scraped account data is used.
• Date: 2026 (the exact run date is stamped when the index runs).

• Method: a mystery-shop. For each provider, a shopper records whether each of the four cost lines (medication, titration, labs, physician follow-up) is disclosed, and whether the all-in monthly cost is visible before account creation or checkout. Each provider gets a transparency grade, and we report the share that hide the all-in figure until checkout.
• Cited supporting data: cash-pay lab list prices are public 2026 figures (PersonalLabs, "How to Get Blood Work Done Without a Doctor: The Complete 2026 Guide", 2026; LabCorp OnDemand, "Weight Management Baseline Test", 2026). Brand-name medication ranges are third-party market estimates (GoodRx, Noom, Health Facts Journal, Telehealth Ally, Ivim Health, May 2026) and are labeled as such, never as sipra data.

Every number in this piece is either a cited public figure or written plainly as to-be-measured. We do not estimate the proprietary stat before we measure it.